Categories
BLOG

weed message board

Weed at St James’s Club? – Antigua Forum

Weed at St James’s Club?

  • United Kingdom Forums
  • United States Forums
  • Europe Forums
  • Canada Forums
  • Asia Forums
  • Central America Forums
  • Africa Forums
  • Caribbean Forums
  • Mexico Forums
  • South Pacific Forums
  • South America Forums
  • Middle East Forums

I’m aware there is a weed problem across the Caribbean, but can anyone tell me how the beaches around the St James’s Club on Antigua are currently affected

I don’t think it’s too much of a problem you should be able to buy it almost anywhere.

LOL, I guessed someone would misinterpret my post!

Haven’t heard of any large amounts of seaweed anywhere on island for a while now. I would say that for the moment it’s unlikely there are any significant amounts anywhere, including St. James.

How can weed be a “problem”? If you don’t like to smoke it . DONT BUY ANY!

-:- Message from Tripadvisor staff -:-

This topic has been closed to new posts due to inactivity. We hope you’ll join the conversation by posting to an open topic or starting a new one.

To review the Tripadvisor Forums Posting Guidelines, please follow this link: http://www.tripadvisor.com/pages/forums_posting_guidelines.html

We remove posts that do not follow our posting guidelines, and we reserve the right to remove any post for any reason.

Answer 1 of 5: Hi there I'm aware there is a weed problem across the Caribbean, but can anyone tell me how the beaches around the St James's Club on Antigua are currently affected Many thanks

Canopy Growth Corporation (WEED.TO)

Previous Close 31.21
Open 30.89
Bid 30.99 x 0
Ask 31.06 x 0
Day’s Range 30.75 – 31.60
52 Week Range 12.96 – 34.80
Volume 1,325,230
Avg. Volume 1,775,215
Market Cap 11.545B
Beta (5Y Monthly) 2.07
PE Ratio (TTM) N/A
EPS (TTM) -4.28
Earnings Date Feb 09, 2021
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 26.49
Fair Value

Subscribe to Premium to view Fair Value for WEED.TO

Related Research

3 Top Canadian Pot Stocks For Your Portfolio

Marijuana is legal across Canada, and sales are soaring. These businesses are a great way to get into this exploding industry.

Better Marijuana Stock to Buy: Cronos or Canopy Growth?

Cronos Group (NASDAQ: CRON) and Canopy Growth (NYSE: CGC) are two marijuana companies that have been around since Canada first legalized medicinal marijuana in 2013. Now that pot legalization is picking up steam in the U.S. as well, marijuana investors are wondering whether the two mavericks can replicate the successes of their premium pot brands down south. Today, let’s look at which of these two high-flying marijuana stocks is the better fit for investors’ portfolios.

Cannabis Stocks Watchlist: Tilray and Canopy Growth Fall

See how Cannabis stocks performed in the market this week along with buy, hold and sell recommendations by TheStreet Quant Ratings.

Why the Bull Run in Canopy Growth Will Last

Since early 2019, Canopy Growth (NASDAQ:CGC) has suffered a grueling bear move. During this period, CGC stock has gone from $50 to just under $24. The market capitalization is now at $8.9 billion. Source: Shutterstock Of course, the whole industry has been under pressure. Just look at the poor performances of stocks like Tilray (NASDAQ:TLRY), Aurora Cannabis (NYSE:ACB), Cronos (NASDAQ:CRON), and Aphria (NASDAQ:APHA). They have all lost significant amounts of their values. There have certainly been good reasons for all this. First of all, the cannabis sector had been bolstered by exuberant expectations and valuations got to unsustainable levels.InvestorPlace – Stock Market News, Stock Advice & Trading Tips Next, the supply-demand situation in Canada got out of whack. There was simply too much production. It also did not help that the Canadian government was not proactive in dealing with black-market activities. 8 Tech Stocks That Could Benefit from a Biden Presidency But despite all this, the fact is that things have been improving. Although, in terms of investing in the sector, it’s still probably best to focus on quality – such as CGC stock. The Latest The most recent earnings report from CGC illustrates how the underlying business is improving nicely. Revenues soared by 77% on a year-over-year basis to 135.3 million CAD, which beat the Wall Street consensus of 117.2 million CAD. A big part of the growth came from the Canadian market for recreational cannabis. The market share is now at an impressive 15.5%, up about 2% on a quarter-over-quarter basis. There were also gains of 1.9% in Ontario, which has the largest population in Canada. Part of the success has been the aggressive rollout of retail operations. But CGC has also the advantage of a portfolio of compelling brands like Martha Stewart CBD, BioSteel, This Works, and Storz & Bickel. It helps that the company has a strategic relationship with Constellation Brands (NYSE:STZ), which is one of the world’s top players in the markets for beer and wine. But the biggest potential catalyst for CGC stock is the massive U.S. market. Joe Biden’s win for the presidency will likely mean more favorable laws for the cannabis industry. He has made it clear that he does not want to incarcerate people for its use. There is also wide-spread public approval for cannabis in America. According to a poll from the Pew Research Center, about 91% said that it should be legal for medical purposes and 59% for recreational use. This sentiment has been borne out by the local results of the 2020 election. There was passage of ballots for legalization in states like Arizona, Mississippi, Montana, New Jersey and South Dakota. In all, there are 36 states that have similar measures. In light of this, there will be more pressure on the federal government to take action. Keep in mind that CGC is well prepared to benefit. The company has been spending large resources in developing the right brands and distribution in the U.S. Another key has been purchase of 70% of the equity in Acreage Holdings (OTCMKTS:ACRGF). The company has an end-to-end platform in 15 states, covering cultivation, processing, dispensing and branding. Bottom Line on CGC Stock CGC has about $1.7 billion in the bank. So yes, the company has enough resources to pursue its U.S. strategy. CGC is also in a position to pick up assets at lower valuations. In fact, there is likely to be a major wave of consolidation in the next couple years. Now the U.S. market will still take some time to get critical mass. But with the Canada picking up momentum – which is also the case with other countries across the globe – CGC stock could remain in the bull mode for some time. On the date of publication, Tom Taulli did not have (either directly or indirectly) any positions in any of the securities mentioned in this article. Tom Taulli (@ttaulli) is the author of various books on investing and technology, including Artificial Intelligence Basics, High-Profit IPO Strategies and All About Short Selling. He is also the founder of WebIPO, which was one of the first platforms for public offerings during the 1990s. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets The post Why the Bull Run in Canopy Growth Will Last appeared first on InvestorPlace.

Is This The Best Way To Play The Second Boom In Marijuana?

Hopes of nationwide legalization have triggered another rally in cannabis shares, and this time it’s all about big data, science and boosting market share

Better Marijuana Stock: Aphria vs. Canopy Growth

Marijuana stocks Aphria (NASDAQ: APHA) and Canopy Growth (NYSE: CGC) have both captured the imaginations of investors looking to grow rich. Both companies are struggling to become profitable, and both are fighting for regional markets in North America amid a growing global cannabis market. Aphria is in the process of finding its identity as a company and establishing itself in its home markets by building its core cannabis brands.

Could Canopy Growth Be a Millionaire-Maker Stock?

Much of the discrepancy in price is because investors overestimated Canopy’s potential in the run-up before the legalization of marijuana in Canada back in October 2018. The stock collapsed in 2019, but investors are once again interested in the company, partly because voters in five states cast their ballots to legalize marijuana this month, adding $2.5 billion of market potential to a green wave sweeping across the U.S. Can Canopy Growth reward marijuana investors and become a millionaire-maker stock through its U.S. expansion efforts?

Too high? Hedge funds unimpressed by Canadian cannabis stocks’ rally

“I wouldn’t recommend investing in Canadian cannabis companies because they have a cost disadvantage versus other operators,” said George Schultze, founder at Schultze Asset, who has exposure to the sector. Cronos Group saw the number of short trades as a percentage of its total traded volume fall slightly to approximately 26.7% for the first half of November, from 28% for the second half of October, regulatory filings showed.

How Canopy Growth Makes Money: Recreational and Medical Marijuana

Canopy Growth Corp. (NYSE: CGC; TSX: WEED) is a Canada-based holding company that produces, distributes, and sells a variety of cannabis and hemp-based products for medical and recreational use. Its products include dried flower, hemp, vape pens and cartridges, THC- and CBD-infused beverages, and edibles.

Why 5 U.S. Cannabis Stocks Will Outperform Amid Federal Ban

Lower-valued American cannabis stocks are set to outperform their Canadian rivals as U.S. legal pot sales outpace those north of the border.

Can Marijuana Help Biden Heal a Divided Nation?

(Bloomberg Opinion) — After five states — Arizona, Mississippi, Montana, New Jersey and South Dakota — passed ballot measures for marijuana use last week, the drug will soon be legal in some form for 70% of the U.S. population. A third of the country won’t even need a medical excuse. But that’s not the surprise.What’s more notable is that unlike in the past, all of this happened without much of a public uproar. To be fair, there have been bigger concerns on Americans’ minds these days. But this is the moment that cannabis companies and their investors have been waiting for: to be considered a legitimate industry rather than a hot voting issue. From here, the goal is to make weed every bit as normal as junk food, wine and other vices long found in stores across America.In order for the industry to flourish it needs the federal government’s help, and the prospects of that are suddenly looking better. Two-thirds of U.S. adults are in favor of marijuana legalization — 91% if you include those who support it at a minimum for medicinal purposes, according to Pew Research Center. That’s more than the number of Americans who support abortion rights or who think human activity contributes to climate change.The partisan gap in attitudes toward pot is also shrinking, with more than half of Republicans saying it should be legalized. In the reliably red state of Mississippi, Initiative 65 — the less-restrictive of two medical marijuana proposals that were on its ballot — was criticized by Governor Tate Reeves as too “liberal” for “non-stoners”:And still it passed by 74%. As Joe Biden takes office in January and the makeup of Congress continues to reflect a divided nation, marijuana may end up being the one issue almost everyone can agree on.The increasing support for pot in red states bodes well for a Senate vote on the Secure and Fair Enforcement Banking Act, which would allow financial institutions to legally do business with marijuana companies. It would be one of the most constructive developments for the industry short of legalizing weed at the federal level.Cannabis companies have reason to be hopeful that a new administration will also usher in other changes such as reclassifying or excluding marijuana from the Controlled Substances Act. De-scheduling the drug would leave states to decide how to handle pot, which may be more palatable to conservatives than attempting to change federal laws, Isaac Boltansky and Merrill Ross, analysts for Compass Point Research & Trading LLC, wrote in an Oct. 26 report. Marijuana is currently considered a Schedule 1 drug, right alongside heroin, in a category reserved for narcotics with the highest potential for abuse and dependence and with no accepted medical use. Examples of Schedule 2 substances are cocaine, fentanyl, methamphetamine and oxycodone — some of them at the root of America’s opioid addiction crisis. For cannabis proponents, that just doesn’t add up. Removing cannabis from the CSA would provide a meaningful benefit to companies’ income statements:The industry is also asking the federal government to allow interstate commerce between states that have legalized. Right now, if a company has a manufacturing plant in, say, Colorado and wants to transport some of that product to its dispensary in Montana, that’s trafficking — a pretty serious crime. And it’s time-consuming and expensive to build infrastructure everywhere.In fact, some of the biggest challenges in getting licensed weed businesses off the ground are around the regulatory hurdles and costly process of having to work piecemeal in expanding around the U.S. That’s helped the illicit weed market maintain a competitive advantage by undercutting prices. In California, where marijuana can be legally purchased, illegal transactions are still estimated to make up the overwhelming majority of sales.It’s no wonder that pot stocks — at one point the darlings of the market — have lost their exuberance this year. The so-called cannabis index has dropped 38%. In one example, beleaguered multistate operator MedMen Enterprises Inc. was forced to walk away from Virginia, where a limited but potentially lucrative medical marijuana market is just beginning to open up; its shares have slumped 73% this year.An unintended effect of squelching the market may be to drive cash-strapped cannabis companies into the arms of food and beverage giants, which are preparing to pounce on pot once laws become more lax. For brewers and tobacco companies, it may be the most promising growth avenue. That said, a bunch of upstarts getting swallowed by behemoths would seem to go against Democratic legislators’ efforts to level competitive playing fields through more aggressive antitrust enforcement. Everyday consumer products are a key way for cannabis companies to target a wider customer base than pot smokers. Canada-based Canopy Growth Corp., valued at $9 billion, wants to start selling drinks containing THC — the psychoactive chemical in cannabis — next year to compete with beer. Even though Canopy is backed by liquor conglomerate Constellation Brands Inc., it’ll be tough going up against Anheuser-Busch InBev AB, which controls 42% of the North American beer market.Bit by bit, things are moving in a positive direction for the industry, albeit slowly. Meanwhile, cannabis companies have strategically entered states where medical marijuana is allowed so that they’re ready to roll once recreational use for adults is made legal. For example, the more immediate winners of last week’s ballot measures include Curaleaf Holdings Inc., a $5.9 billion company that holds the No. 1 market share in New Jersey and No. 2 in Arizona, and Harvest Health & Recreation Inc., which gets 50% of its sales from Arizona, according to a Nov. 4 report by Pablo Zuanic, an analyst for Cantor Fitzgerald & Co. New York and Pennsylvania are expected to be next, with budget shortfalls caused by Covid-19 potentially incentivizing them to move faster on the issue.At the national level, if Biden is looking for common ground with Republicans, marijuana of all things seems like a reasonable place to start. The year 2020 truly is bizarre. (Corrects third-to-last paragraph to clarify that Canopy is based in Canada, with a U.S.-listed stock. )This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Tara Lachapelle is a Bloomberg Opinion columnist covering the business of entertainment and telecommunications, as well as broader deals. She previously wrote an M&A column for Bloomberg News.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

Marijuana Companies That Legally Export Cannabis to the U.S.

With recreational cannabis use legal among adults in Canada and marijuana companies on the rise, there is an opportunity for imports to the U.S.

Martha Stewart And Canopy Growth Launch CBD Wellness Gummy Sampler

Martha Stewart is releasing a new holiday-inspired gummies line.The “Domestic Diva” is partnering with Canopy Growth Corp. (TSX: WEED) (NYSE: CGC) to launch the Martha Stewart CBD Wellness Gummies Sampler.Back in February 2019, Stewart took an advisory role at the cannabis company, and then — this past September — the partnership launched a new line of hemp-derived supplements.Martha Stewart’s CBD product line contained gummies, oil drops and softgels.The newly-released Martha Stewart CBD Wellness Gummies Sampler is said to be influenced by “the French confection pate de fruits.” It contains 15 seasonal flavors like Quince, Passion Fruit, and Pink Grapefruit.One box costs $64.99 and contains 60 naturally-flavored 10 milligrams of CBD gummies. It can be pre-ordered at Canopy Growth’s one-stop e-commerce website, ShopCanopy.com.”Holiday gift giving and receiving should be a joyous and fun occasion. In my experience, the gifts that are most appreciated are both luxurious and practical,” Stewart says. “Presented in a special gift box, my gummy sampler tastes like an elegant and delicious treat which delivers all the wellness benefits of CBD, making it the perfect way to indulge your loved ones, or yourself, without spending a fortune.”Sol Clahane, Canopy VP and Managing Director, praised the collaboration.The goal is “to help bring Martha’s vision for this very special CBD wellness gummy sampler to life with an array of truly unique and very delicious flavors unlike anything else on the market,” she said. “It’s a timely addition to her already popular line of CBD wellness products.”Courtesy imageSee more from Benzinga * Click here for options trades from Benzinga * Earnings Update: Aurora, Canopy Growth, Canopy Rivers And Zynerba Each Post Results(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Canopy Growth launches Martha Stewart CBD gummy sampler

Canopy Growth Corp. said Wednesday it has released its Martha Stewart CBD Wellness Gummies Sampler in time for the holiday season. The 60-count box features 15 season flavors that include Passionfruit, Calamondin and Quince in 10mg CBD gummies. The box costs $64.99 and is available for pre-order on Canopy’s ShopCanopy.com website. Canopy, the biggest cannabis company by market cap, reported its latest quarterly earnings this week and highlighted high expectations for its collaboration with Martha Stewart. Canopy’s U.S. listed shares were down 1.4% premarket, but have gained 12% in the year to date, while the Cannabis ETF has fallen 14% and the S&P 500 has gained 9.7%.

Martha Stewart Releases Delicious 15-Flavor CBD Wellness Gummy Holiday Sampler in Collaboration with Canopy Growth Corporation and Marquee Brands

Canopy Growth Corporation (TSX: WEED) (NYSE: CGC), a world-leading diversified cannabis, hemp, and cannabis device company, has released a highly giftable Martha Stewart CBD Wellness Gummies Sampler just in time for the holidays. Inspired by the French confection pâte de fruits, this elegant 60-count sampler box features 15 seasonal flavors such as Passionfruit, Calamondin and Quince.

Cantor Raises Canopy Growth Target After September Quarter Print

Canopy Growth Corp’s (NYSE: CGC) is likely to be supported by growth in the Canadian recreation business, continued progress by the strategic units and improving profitability, according to Cantor Fitzgerald.The Canopy Growth Analyst: Pablo Zuanic maintained a Neutral rating for Canopy Growth, while raising the price target from CA$28 to CA$29.The Canopy Growth Thesis: Growth in the Canadian recreation business, strategic units and profitability should offset concerns around a potential slowdown in the international medical business, Zuanic said in the note.”While recent increased reliance on the domestic value flower segment remains a concern for us, we realize the company is following a multi-pronged approach in Canada. Also, it benefits from operating several, rather profitable, non-cannabis businesses,” he wrote.”Regardless of when cannabis becomes federally permissible in the US, we believe the company has several ways to continue to add value to the “optionality” it enjoys from its US “diversified ecosystem”,” the analyst noted.He said that the relationship with Constellation Brands, Inc. (NYSE: STZ) goes beyond just the balance sheet.Latest Ratings for CGC DateFirmActionFromTo Feb 2020Stifel NicolausMaintainsBuy Jan 2020BMO CapitalUpgradesMarket PerformOutperform Nov 2019Bank of AmericaUpgradesNeutralBuy View More Analyst Ratings for CGC View the Latest Analyst RatingsSee more from Benzinga * Click here for options trades from Benzinga * Levi Strauss Positioned For Quick Recovery, BofA Says In Upgrade * Pfizer Analyst: Coronavirus Vaccine Moving Closer To Emergency Use Authorization(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Tilray’s Earnings Loss Was Less Than Feared. What Wall Street Is Saying.

(TLRY) reported a smaller net loss than Wall Street expected for its third quarter, but the stock sank in Tuesday trading. The company’s (ticker: TLRY) net loss of two cents per share was ahead of consensus estimates calling for a loss of 21 cents a share. CEO Brendan Kennedy said in a news release the company has made progress despite challenges related to the Covid-19 pandemic.

Is The World’s Biggest Marijuana Stock A Buy After The Election?

Canopy Growth stock broke out in November, as investors’ hopes for nationwide pot legalization grew after the election.

Cannabis rally takes a pause as lackluster earnings make gains look overdone

The strong rally that has propelled cannabis stocks higher since Democrat Joe Biden won the 2020 presidential election took a pause on Tuesday, as analysts weighed in on earnings from three industry heavyweights and found little to justify some of the explosive gains.

Should You Buy Marijuana Stocks After The 2020 Election?

Are marijuana stocks a good buy amid the coronavirus pandemic? The marijuana industry gets lots of hype, but pot stocks have poor fundamentals and technicals.

Find the latest CANOPY GROWTH CORPORATION (WEED.TO) stock quote, history, news and other vital information to help you with your stock trading and investing.